Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance

LOS ANGELES, CA--(Marketwired - Mar 14, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today announced initiation of its Phase 2B/3 clinical trial of RP-G28, which has the potential to be the first FDA-approved treatment for lactose intolerance.

The trial is a double-blind, placebo-controlled, three arm, multicenter study enrolling approximately 350 patients with Lactose Intolerance symptoms. Patients will undergo a 30-day treatment process, followed by a 30-day post-treatment evaluation. In addition, the study will further evaluate participant's microbiome, expanding knowledge of the effects RP-G28 may have on positively adapting and shifting the gut microbiota for health benefits. The company estimates that the study will take approximately 10 months to complete and top-line data is expected in early 2017. One can learn more about participating in the clinical trial at www.LactoseTrial.com or by calling toll-free 877-852-9598.

Andrew J. Ritter, Founder and President of Ritter Pharmaceuticals, stated, "The initiation of this trial demonstrates continued progress in the pursuit of developing the first FDA approved treatment for lactose intolerance. It is one of the first therapeutic agents shown to positively adapt the microbiome of lactose intolerance patients. There is a large market opportunity for a safe and effective treatment for this condition, and we believe that our treatment can have a tremendous impact on the day-to-day lives of millions who suffer from lactose intolerance around the globe."

About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of the gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.

Forward-Looking Statements
This release may contain forward-looking statements, which express the current beliefs and expectations of Ritter Pharmaceuticals' management. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.